Lonza and DiNAQOR AG, a global gene therapy platform company, announced a strategic collaboration to advance DiNAQOR's preclinical programs for the treatment of cardiac myosin-binding protein-C (MYBPC3) cardiomyopathies, a genetic condition that can result in heart failure.
Lonza and DiNAQOR announce strategic collaboration to advance gene therapy programs for patients with monogenic cardiomyopathies. Photo: courtesy of Darwin Laganzon from Pixabay.
Under the terms of the collaboration, Lonza will provide DiNAQOR preclinical, clinical and commercial production support for the companyslead preclinical program DiNA-001, anadeno-associated virus (AAV) gene therapy program for patients with MYBPC3-linked cardiomyopathy. Lonzas state-of-the-art cell-and-gene-therapy manufacturing facility in Houston, TX (US) will handle all product supply for DiNA-001.
Quote from Alberto Santagostino, SVP Head of Cell & Gene Technologies, Lonza Pharma & Biotech:
DiNAQOR has established an innovative gene therapy platform that will allow for the evaluation of this promising treatment for monogenic cardiomyopathies. DiNAQOR represents the truly trailblazing companies that we strive to empower in the cell and gene therapy space and we are fully committed to the DiNAQOR team as they seek to advance novel treatment options for people living with heart disease.
Quote from Dr. Johannes Holzmeister, Chairman and Chief Executive Officer, DiNAQOR:
Lonza is a leader in the manufacturing of adeno-associated virus gene therapy vectors and is the optimal partner to help us rapidly advance and scale the production of DiNA-001 from early-stage clinical trials through commercialization. Precise and rapid genetic diagnostics, leading analytics, and an adequate product supply for all stages of clinical development and commercialization are necessary to bring these potentially transformational gene therapies to patients suffering from heart failure. We are excited to collaborate with Lonza on this critical initiative.
Through this partnership, DiNAQOR will be able to leverage Lonzas extensive, dedicated teams and laboratories for viral-vector process-development, located in Houston (US).
In addition to its cardiac gene therapy platform, DiNAQOR is also developing a local-regional delivery system for the heart. This will allow the company to route gene therapy directly to the cardiac muscle maximizing biodistribution and transduction of the cardiomyocytes. This approach will look to minimize potential adverse effects of systemic gene therapy delivery.
Source: Company Press Release
The rest is here:
- Cardiomyopathy what it is and types British Heart Foundation [Last Updated On: April 12th, 2018] [Originally Added On: April 12th, 2018]
- Cardiomyopathy what it is and types British Heart ... [Last Updated On: May 28th, 2018] [Originally Added On: May 28th, 2018]
- Cardiomyopathy - what it is and types - British Heart ... [Last Updated On: June 6th, 2018] [Originally Added On: June 6th, 2018]
- Cardiomyopathy Symptoms, Types, Treatment & Prognosis [Last Updated On: November 5th, 2018] [Originally Added On: November 5th, 2018]
- Mark Drazner, M.D.: Internal Medicine | Cardiomyopathies ... [Last Updated On: December 20th, 2018] [Originally Added On: December 20th, 2018]
- Overview of Cardiomyopathies - Cardiovascular Disorders ... [Last Updated On: December 27th, 2018] [Originally Added On: December 27th, 2018]
- Cardiomyopathy | Cleveland Clinic [Last Updated On: April 24th, 2019] [Originally Added On: April 24th, 2019]
- Cardiomyopathy | pathology | Britannica.com [Last Updated On: April 29th, 2019] [Originally Added On: April 29th, 2019]
- Cardiomyopathy | Children's Hospital of Philadelphia [Last Updated On: April 29th, 2019] [Originally Added On: April 29th, 2019]
- Cardiac Surgery Instruments Market Prospects and Growth Assessment - TodayTimes [Last Updated On: September 22nd, 2019] [Originally Added On: September 22nd, 2019]
- Cardiovascular Genomic Diagnostics Market to Record an Exponential CAGR by 2025 - Rapid News Network [Last Updated On: September 22nd, 2019] [Originally Added On: September 22nd, 2019]
- Cardiovascular Genomic Diagnostics Market Estimated to Expand at a Robust CAGR over 2018 2028 - Space Market Research [Last Updated On: October 9th, 2019] [Originally Added On: October 9th, 2019]
- Cytokinetics Announces Presentation of Additional Analyses From FORTITUDE-ALS at the 18th Annual NEALS Meeting - Yahoo Finance [Last Updated On: October 9th, 2019] [Originally Added On: October 9th, 2019]
- Cardiac Surgery Instruments Market to be Fueled by Increasing Threat of Cardiovascular Diseases - Online News Guru [Last Updated On: October 21st, 2019] [Originally Added On: October 21st, 2019]
- Cell Culture Protein Surface Coating Market Current Outlook Of Industry & Forecast 2017 2025 - Health News Office [Last Updated On: October 24th, 2019] [Originally Added On: October 24th, 2019]
- Cytokinetics to Announce Third Quarter Results on October 31, 2019 - Yahoo Finance [Last Updated On: October 24th, 2019] [Originally Added On: October 24th, 2019]
- Lonza and DiNAQOR AG Announce Strategic Collaboration to Advance Gene Therapy Programs for Patients with Monogenic Cardiomyopathies - PRNewswire [Last Updated On: November 29th, 2019] [Originally Added On: November 29th, 2019]
- Cytokinetics Announces New Results Presented at the International Symposium on ALS/MNDSubgroup Analyses of FORTITUDE-ALS on Effects of Reldesemtiv... [Last Updated On: December 8th, 2019] [Originally Added On: December 8th, 2019]
- Cell Culture Protein Surface Coating Market Competitive Environment and Higher Growth Rate with Forecast to 2025 - Filmi Baba [Last Updated On: January 4th, 2020] [Originally Added On: January 4th, 2020]
- New PET tracer provides insight on cardiac failure risk after heart attack - DOTmed HealthCare Business News [Last Updated On: January 12th, 2020] [Originally Added On: January 12th, 2020]
- PET tracer can help fight heart attacks earlier in the process - Health Imaging [Last Updated On: January 12th, 2020] [Originally Added On: January 12th, 2020]
- Atrial fibrillation in athletes - CMAJ [Last Updated On: January 13th, 2020] [Originally Added On: January 13th, 2020]
- Cytokinetics Announces Publication Relating to Design of GALACTIC-HF, a Phase 3 Clinical Trial of Omecamtiv Mecarbil in Patients With Heart Failure -... [Last Updated On: February 9th, 2020] [Originally Added On: February 9th, 2020]
- Cytokinetics to Announce Fourth Quarter Results on March 3, 2020 - Yahoo Finance [Last Updated On: February 25th, 2020] [Originally Added On: February 25th, 2020]
- Stealth BioTherapeutics to Present at 40th Annual Cowen Health Care Conference - PRNewswire [Last Updated On: February 27th, 2020] [Originally Added On: February 27th, 2020]
- Cell Culture Protein Surface Coating Market Analysis On Trends & Need 2025 - 3rd Watch News [Last Updated On: March 18th, 2020] [Originally Added On: March 18th, 2020]
- Heart patients dont need to panic: Doc - The Tribune India [Last Updated On: March 18th, 2020] [Originally Added On: March 18th, 2020]
- Stealth BioTherapeutics to Report Full Year 2019 Financial Results on Wednesday, April 1, 2020 - Yahoo Finance [Last Updated On: April 1st, 2020] [Originally Added On: April 1st, 2020]
- Stealth BioTherapeutics Reports Fiscal Year 2019 Financial Results And Recent Business Highlights - BioSpace [Last Updated On: April 1st, 2020] [Originally Added On: April 1st, 2020]
- Stealth BioTherapeutics to Report First Quarter 2020 Financial Results on Thursday, May 7, 2020 - Tewksbury town crier [Last Updated On: May 5th, 2020] [Originally Added On: May 5th, 2020]
- BioMarin broadens its gene therapy horizons with a new R&D alliance in rare cardio cases - Endpoints News [Last Updated On: May 5th, 2020] [Originally Added On: May 5th, 2020]
- Tenaya Therapeutics to Present Preclinical Data at 2020 Annual Meeting of the American Society of Gene & Cell Therapy - thepress.net [Last Updated On: May 12th, 2020] [Originally Added On: May 12th, 2020]
- Stealth BioTherapeutics to Present at Upcoming Investor Conferences in September - Yahoo Finance [Last Updated On: September 12th, 2020] [Originally Added On: September 12th, 2020]
- What we know about what it's like to recover from Covid-19 and its long-term effects - Local News 8 - LocalNews8.com [Last Updated On: October 7th, 2020] [Originally Added On: October 7th, 2020]
- Should You Buy Myokardia Inc (MYOK) Stock After it Is Up 64.52% in a Week? - InvestorsObserver [Last Updated On: October 7th, 2020] [Originally Added On: October 7th, 2020]
- Heart Failure from ATTRwt Amyloid Cardiomyopathy is Associated with Poor Prognosis - DocWire News [Last Updated On: October 7th, 2020] [Originally Added On: October 7th, 2020]
- Relaxera and CBL Patras Announce Exclusive Agreement on Manufacturing and Sales of Synthetic Human R - PharmiWeb.com [Last Updated On: December 16th, 2020] [Originally Added On: December 16th, 2020]
- Counties combine push for more vaccines - The Record Newspapers - TheRecordLive.com [Last Updated On: January 26th, 2021] [Originally Added On: January 26th, 2021]
- Vet Speak: Cats are very good at hiding the signs of heart disease - RossShire Journal [Last Updated On: January 26th, 2021] [Originally Added On: January 26th, 2021]
- Stealth BioTherapeutics Reports First Quarter 2021 Financial Results And Recent Business Highlights - Yahoo Finance [Last Updated On: May 25th, 2021] [Originally Added On: May 25th, 2021]
- Suspicion of Frasier's syndrome in the nephrology unit | IMCRJ - Dove Medical Press [Last Updated On: August 14th, 2021] [Originally Added On: August 14th, 2021]
- Delta has set back herd immunity estimates. Heres how that affects the course of the pandemic - The Dallas Morning News [Last Updated On: August 14th, 2021] [Originally Added On: August 14th, 2021]
- Hypertrophic Cardiomyopathy Market to be Driven by the Emergence of Novel Pharmacotherapies & Gene-directed Approaches at a 22.24% CAGR During the... [Last Updated On: August 14th, 2021] [Originally Added On: August 14th, 2021]
- Stealth BioTherapeutics Reports Third Quarter 2021 Financial Results and Recent Business Highlights - PRNewswire [Last Updated On: November 18th, 2021] [Originally Added On: November 18th, 2021]
- Cytokinetics to Participate in the Piper Sandler 33rd Annual Virtual Healthcare Conference - GuruFocus.com [Last Updated On: November 18th, 2021] [Originally Added On: November 18th, 2021]
- What is cardiac transplantation? An overview - Emergency Live International [Last Updated On: October 6th, 2022] [Originally Added On: October 6th, 2022]
- Fixing Heart Failure Workforce Issues: Baby Steps Start This Year - Medpage Today [Last Updated On: January 10th, 2023] [Originally Added On: January 10th, 2023]
- Inherited Cardiac Disease Genetic Diagnoses Linked to Ancestry ... - GenomeWeb [Last Updated On: January 10th, 2023] [Originally Added On: January 10th, 2023]
- VIDEO: Using genetics in cardiology to enable earlier interventions - Cardiovascular Business [Last Updated On: January 10th, 2023] [Originally Added On: January 10th, 2023]
- Ahmad Masri, MD, MS: 2024 Update on Development and Future of Cardiac Myosin Inhibitor Class - MD Magazine [Last Updated On: February 20th, 2024] [Originally Added On: February 20th, 2024]